Glucagon-Like Peptide 1 (GLP-1) Receptor Variants and Glycemic Response to Liraglutide: A Pharmacogenetics Study in Iranian People with Type 2 Diabetes Mellitus.

What the trial testedas reported · 233 people · 2024

Not counted

3.3×1.4× to 7.7×

Bigger than 8 in 10 for glycemic control

As reported

OR 3.28, 95% CI 1.41–7.65

Not counted

2.5×1× to 6.1×

Bigger than 7 in 10 for glycemic control

As reported

OR 2.52, 95% CI 1.03–6.13

the abstract, start to end

… homozygous states (recessive model: OR 3.28, 95% CI 1.41-7.65, P = 0.006; codominant model: OR 2.52, 95% CI 1.03-6.13, P = 0.04).

← favours treatmentfavours comparator →

could be chance

Glycemic control

OR 3.281.41–7.65

Glycemic control

OR 2.521.03–6.13

GLP-1 receptor agonistsGlycemic control

1 / 3

2024

2025

2026

this paperpooled ittrialcites it